patent.fyi
Applications  /  US 2026/0356851
United States Patent Application Publication

US 2026/0356851 A1

Published
Nov 12, 2026
Filed
May 16, 2024
Earliest date on the face
May 16, 2023
Classification
C07D 498/16
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Dimethylsilyl group at X

What ifWhat if X were a dimethylsilyl group?
Claim language“X is O, NR11, CR15R16, C(O), S, S(O) or S(O)2”

The silicon atom forms a single bond to each of the two atoms flanking X. Two methyl groups complete its four bonds, and the silicon atom occupies one position in the ring.

1.2Phenyl group on nitrogen

What ifWhat if the cyclic substituent at R11 were phenyl?
Claim language“C3-8 cycloalkyl, and 3-8 membered heterocyclyl”

The nitrogen at X bonds directly to a carbon of the six-membered aromatic ring. The phenyl group projects from the core as a rigid, planar substituent.

1.4Seven-membered spiro ring

What ifWhat if the two substituent positions on the shared carbon closed into a seven-membered carbocycle?
Claim language“form C3-6 cycloalkyl”

A chain of six methylene groups joins the two substituent bonds at the shared carbon. The chain and shared carbon form a cycloheptane ring that meets the core at that single atom.

1.5Carbon at the Y position

What ifWhat if Y were an aromatic carbon bearing hydrogen and Z remained nitrogen?
Claim language“Y is N, and Z is N”

The carbon at Y bonds to the two neighboring ring atoms and to hydrogen. It contributes one electron to the aromatic π system, and the nitrogen at Z retains its lone pair.

1.6Fluorine at the Y position

What ifWhat if the carbon at Y bore fluorine while Z remained nitrogen?
Claim language“Y is C—CN”

Fluorine forms a direct bond to the ring carbon at Y. The carbon remains part of the aromatic π system, and the carbon–fluorine bond places a local dipole at that position.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Tricyclic probes for stationary phase testing

A chromatographic stationary phase test uses two tricyclic compounds with the same core and different terminal ring groups. One carries a phenyl group at R18 and the other carries a pyridinyl group at R18, with direct attachment in both compounds. Separate injections establish peak identities, and a mixed injection measures the retention selectivity of the stationary phase.

Component substitution

Methylene linker for the terminal ring

A methylene group replaces the oxygen linker between the tricyclic core and the terminal phenyl ring. The resulting side chain attaches to the core through a carbon–carbon bond and has the connectivity core–CH2–phenyl. A matched pair uses the same core stereochemistry and peripheral substituents to isolate the effect of the linker on chromatographic retention.

Parameter or scale variation

Ring expansion at the core junction

A spirocycloheptane occupies the core position where X is a substituted carbon. A six-methylene tether connects both substituent bonds of that carbon, forming a seven-membered carbocycle that shares one atom with the tricyclic core. A matched series uses four-, five-, and six-methylene tethers to compare five-, six-, and seven-membered spiro rings under the same measurement conditions.

Combination with existing systems

Tricyclic standards on a fraction collector

A preparative liquid chromatograph connects through an ultraviolet detector to a triggered fraction collector. The injection contains a mixture of tricyclic compounds with distinct terminal ring groups. An analytical scouting run identifies the collection windows, and the preparative system offsets those windows by the detector-to-collector tubing volume divided by the flow rate.

Humidity controlled analysis of tricyclic solvates

A humidity-controlled powder X-ray diffractometer holds a crystalline tricyclic solvate in a sample chamber supplied with mixed dry and humid gas streams. The chamber maintains a fixed temperature while relative humidity advances through preset steps. Diffraction patterns collected after equilibration at each step track changes in the crystalline phase as the sample takes up or loses water.

Automated or data-driven variant

Software enumeration of tricyclic stereoisomers

A molecular graph enumerator takes a connection table for a fully specified tricyclic core and a library of side chains with marked attachment atoms. It attaches each side chain, checks valence, and enumerates configurations at unspecified stereocenters. Canonical isomeric representations remove duplicate structures, and each output record stores the core identifier, side-chain identifier, and stereochemical assignment.

Specific version of a part

Deuterium at the R15 position

R15 is deuterium, and the associated scaffold carbon forms a direct carbon–deuterium bond. The isotope changes the mass at that position while preserving the carbon’s bonding pattern.

Double bond in the core

The indicated bond is a carbon–carbon double bond, and R6 and R8 are absent. The two carbons have trigonal planar geometry, and the π bond restricts rotation about their shared axis.

Single oxygen atom linker

L1 is an oxygen atom that forms one single bond to the core and one to R18. With phenyl as R18, the resulting substituent is a phenoxy group attached through oxygen.

Para fluorinated phenyl group

R18 is a six-membered phenyl ring with fluorine at the carbon opposite the attachment point. The attachment and fluorine occupy positions 1 and 4 of the ring.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2015/0218187 A1
Published
Aug 6, 2015
Filed
Oct 1, 2013
Class
C07D 498/04
Document BUS 2021/0032249 A1
Published
Feb 4, 2021
Filed
Mar 2, 2018
Class
C07D 487/04
Claim 1
Document A
Document B
1.1X is O, NR11, CR15R16, C(O), S, S(O) or S(O)2
X and Y are each independently selected from the group consisting of a bond, —NR7—, —CR7R8—, —S(O)m—, ring A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH2)nOR9, —(CH2)nSR9, —(CH2)
B · US 2021/0032249 A1 · claim 1
1.2R11 is independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-OH, —(C1-6 alkyl)-CN, —CO(C1-6 alkyl), —CONH2, —CONH(C1-6 alkyl), —CON(C1-6 alkyl)2, C3-8 cycloalkyl, and 3-8 membered heterocyclyl
R6 is selected from hydrogen, cyano, alkyl or haloalkyl;
A · US 2015/0218187 A1 · ¶
1.3R15 and R1-6 are each independently selected from hydrogen, deuterium, halogen, —CN, —OH, —NH2, C1-6 alkyl, C1-6 haloalkyl, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-OH, —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CO(C1-6 alkyl), —CONH2, —CONH(C1-6 alkyl), —CON(C1-6 alkyl)2, C3-8 cycloalkyl, and 3-8 15 membered heterocyclyl
Ra and Rb are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl; or Ra and Rb taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally have additional heteroatoms selected from O, N or S; p=0-2; n=0-4
A · US 2015/0218187 A1 · ¶
1.4or R15 and R1-6 together with the carbon atom to which they are attached form C3-6 cycloalkyl or 3-6 membered heterocyclyl
The above substituents can be bonded to different carbon atoms to form a carbon chain, or can be bonded to one carbon atom to form a cycloalkyl.
B · US 2021/0032249 A1 · ¶ 114
1.5Y is N, and Z is N
1.6or Y is C—CN, and Z is N or Z is CR2
1.7represents a double bond or a single bond, and when represents a double bond R6 and R8 are absent
1.8p is 0, 1 or 2
1.9R1 is —L1—R18
* represents point of attachment to L2. rings A and B represent a spirocyclic ring system wherein, A and B are same or different and independently represents a three to eight membered ring which may be saturated or partially unsaturated optionally having up to four heteroatoms selected from O, N or S; ring C is absent or is 6 membered aromatic or heteroaromatic ring system; ring D is selected from cycloalkyl, aryl, heterocyclyl or heteroaryl; rings E represents a 5-12 membere
A · US 2015/0218187 A1 · ¶
1.10L1 is absent, or L1 is NR1, O, C(O), S, S(O) or S(O)2
L1, L2, L3, L4 and L5 are independently absent or is C1-4 alkylene wherein one or more methylene groups is optionally replaced by hetero atoms or groups such as —O—, —S(O)p—, —N(R6)—, —C(O)—, —C(S)— or —(CRaRb)—; alkylene is optionally substituted with hydroxy, amino, aminoalkyl, cyano, halogen, haloalkyl, perhaloalkyl, carboxy, carboxyalkyl, alkylcarboxy, alkoxy, hydroxyalkyl, alkoxyalkyl, alkoxyalkoxy or alkyl;
A · US 2015/0218187 A1 · ¶
1.11R18 is selected from 6-14 membered aryl, 5-14 membered heteroaryl, C3-10 cycloalkyl, and 4-14 membered heterocyclyl, each of which is optionally substituted with one or more groups independently selected from: halogen, —CN, —OH, —SH, —SF5, oxo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —O(C3-8 cycloalkyl), —O(3-8 membered heterocyclyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —S(C3-8 cycloalkyl), —S(3-8 membered heterocyclyl), —OC(O)NRaRb, —NRaC(O)ORc, —NRaC(O)Rd, —NRaRb, —C(O)NRaRb, —C(O)ORc, —C(O)Rd, —S(O)2Rf, and —S(O)2NRaRb
ring A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(O)OR9, —(CH2)nS(O)mR9, —(CH2)nNR10R11, —(CH2)nC(O)NR10R11, —(CH2)nC(O)NHR10, —(CH2)n
B · US 2021/0032249 A1 · ¶ 11
1.12wherein the C1-6 alkyl is optionally substituted with one or more deuterium, and the C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl and 3-8 membered heterocyclyl are each optionally substituted with one or more halogen R2 is selected from hydrogen, halogen, —CN, —OH, —SH, oxo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —O(C3-8 cycloalkyl), —O(3-8 membered heterocyclyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —S(C3-8 cycloalkyl), —S(3-8 membered heterocyclyl), —OC(O)NRaRb, —NRaC(O)ORe, —NRaC(O)Rd, —NRaRb, —C(O)NRaRb, —C(O)ORc, —C(O)Rd, —S(O)2Rf, and —S(O)2NRaRb wherein the C1-6 alkyl is optionally substituted with one or more deuterium, and the C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl and 3-8 membered heterocyclyl are each optionally substituted with one or more halogen R3 is selected from hydrogen, —OH, —SH, —NH2, C1-6 alkyl, C1-6 haloalkyl, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —NH(C1-6 alkyl), —N(C1-6 alkyl)2, C3-8 cycloalkyl, 4-10 membered heterocyclyl, and —O—L2—R12 wherein the C3-8 cycloalkyl and 4-10 membered heterocyclyl are each optionally substituted with one or more groups independently selected from: deuterium, halogen, —CN, —OH, —SH, oxo, —NH2, C1-6 alkyl, C1-6 alkylidene, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), and —S(C1-6 alkyl) wherein the C1-6 alkylidene is optionally substituted with one or more halogen L2 is absent, or L2 is C1-6 alkylene or C3-8 cycloalkylene wherein the C1-6 alkylene and C3-8 cycloalkylene are each optionally substituted with one or more deuterium or halogen R12 is C3-10 cycloalkyl or 4-12 membered heterocyclyl, each of which is optionally substituted with one or more groups independently selected from: deuterium, halogen, —CN, —OH, —SH, oxo, C1-6 alkyl, C1-6 alkylidene, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, —(C1-6 alkyl)-O—(C1-6 alkyl), —O(C1-6 alkyl), —O(C1-6haloalkyl), —O(C3-8 cycloalkyl), —O(3-8 membered heterocyclyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —S(C3-8 cycloalkyl), —S(3-8 membered heterocyclyl), —OC(O)NRaRb, —NRaC(O)ORe, —NRaC(O)Rd, —NRaRb, —C(O)NRaRb, —C(O)ORd, —C(O)Rd, —S(O)2Rf, and —S(O)2NRaRb wherein the C1-6 alkyl, C1-6 alkylidene, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl and 3-8 membered heterocyclyl are each optionally substituted with one or more R17 R17 is selected from deuterium, halogen, —CN, —OH, —SH, oxo, C1-6 alkyl, C1-6 alkylidene, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —NRaRb, —NHCO(C1-6 alkyl), —CO(C1-6 alkyl), —CONH2, —CONH(C1-6 alkyl), —CON(C1-6 alkyl)2, —S(O)2(C1-6 alkyl), —S(O)2NH(C1-6 alkyl), and —S(O)2N(C1-6 alkyl)2 wherein the 3-8 membered heterocyclyl is optionally substituted with one or more groups independently selected from: deuterium, halogen, —CN, —OH, oxo, —NH2, C1-6 alkyl, C1-6 alkylidene, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —CO(C1-6 alkyl), and —S(O)2(C1-6 alkyl) R4 is selected from C1-6 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, 4-12 membered heterocyclyl and 5-12 membered heteroaryl, each of which is optionally substituted with one or more R13 R13 is selected from deuterium, halogen, —CN, —OH, —SH, oxo, —NH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —NHCO(C1-6 alkyl), —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CO(C1-6 alkyl), —CONH2, —CONH(C1-6 alkyl), —CON(C1-6 alkyl)2, —S(O)2(C1-6 alkyl), —S(O)2NH(C1-6 alkyl), and —S(O)2N(C1-6 alkyl)2 wherein the C3-8 cycloalkyl, 3-8 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl are each optionally substituted with one or more R14 R14 is independently selected from deuterium, halogen, —CN, —OH, —SH, oxo, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl)-, —O(C3-8 cycloalkyl), —O(3-8 membered heterocyclyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —S(C3-8 cycloalkyl), —S(3-8 membered heterocyclyl), —NRaC(O)Rd, —NRaRb, —C(O)NRaRb, —C(O)ORc, —C(O)Rd, —S(O)2Rf, and —S(O)2NRaRb wherein the C1-6 alkyl is optionally substituted with one or more deuterium, and the C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with one or more halogen R5, R6, R7, R8, R9 and R10 are each independently selected from hydrogen, deuterium, halogen, —CN, —OH, —SH, oxo, —NH2, C1-6 alkyl, C1-6 haloalkyl, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-OH, —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CO(C1-6 alkyl), —CONH2, —CONH(C1-6 alkyl), —CON(C1-6 alkyl)2, C3-8 cycloalkyl, and 3-8 membered heterocyclyl or R5 and R6, R7 and R8, R9 and R10, R5 and R7, R7 and R9, or R5 and R9 together with the carbon atoms to which they are attached form C3-6 cycloalkyl or 3-6 membered heterocyclyl or R4 and R5 together with the nitrogen atom and carbon atom to which they are attached form 5-12 membered heteroaryl, which is optionally substituted with one or more R14 or R4 and R5 together with the nitrogen atom and carbon atom to which they are attached form 4-10 membered heterocyclyl wherein the 4-10 membered heterocyclyl is substituted with one or more groups independently selected from: C3-8 cycloalkyl, 3-8 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl the 4-10 membered heterocyclyl is further optionally substituted with one or more groups independently selected from: deuterium, halogen, —CN, —OH, —SH, oxo, —NH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-CN, —O(C1-6 alkyl), —O(C1-6 haloalkyl), —S(C1-6 alkyl), —S(C1-6 haloalkyl), —NHCO(C1-6 alkyl), —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CO(C1-6 alkyl), —CONH2, —CONH(C1-6 alkyl), —CON(C1-6 alkyl)2, —S(O)2(C1-6 alkyl), —S(O)2NH(C1-6 alkyl), and —S(O)2N(C1-6 alkyl)2 wherein the C3-8 cycloalkyl, 3-8 membered heterocyclyl, 6-10 membered aryl and 5-10 membered heteroaryl are each optionally substituted with one or more R14 Ra, Rb, Rc, Rd and Rf are each independently selected from hydrogen, C1-6 alkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl wherein the C1-6 alkyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with one or more groups independently selected from: halogen, —CN, —OH, —O(C1-6 alkyl), C3-8 cycloalkyl, 3-8 membered heterocyclyl, —NRgRh, —C(O)NRgRh, and —NRgC(O)Ri wherein Rg, Rh and Ri are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-OH, —(C1-6 alkyl)-CN, —(C1-6 alkyl)-NH2, —(C1-6 alkyl)-NH(C1-6 alkyl), —(C1-6 alkyl)-N(C1-(alkyl)2, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl or Ra and Rb together with the nitrogen atom to which they are attached form 3-8 membered heterocyclyl.
R1, R2, R3, R4 and R5 are independently selected from hydrogen, halo, cyano, nitro, —(CRaRb)nOR7, —(CRaRb)nC(O)R7, —(CRaRb)nSR7, —(CRaRb)nCOOR7, —(CRaRb)nNR8R9, —(CRaRb)nC(O)NR8R9, —(CRaRb)nNR8C(O)OR7, —(CRaRb)nNR8C(O)NR8R9, —NR8S(O)2R7, —S(O)pR7, —SO3H, —S(O)2NR8R9, azido, oxo, thiocarbonyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, cyanoalkyl, cyanoalkylcarbonyl, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, alkoxyalkoxy, alkoxyalkoxyalkyl, cycloalkyl, cycloalkenyl, cycloa
A · US 2015/0218187 A1 · ¶
or, R3 and R4 are bonded to form a heterocyclyl or heteroaryl, any two substituents on the heterocyclyl or heteroaryl can form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, haloalkyl, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocycl
B · US 2021/0032249 A1 · ¶ 29

An empty cell means only that no passage was reproduced there.

Statements in these documents
Therefore, there remains a need for discovering novel DGAT1 inhibitors possessing desirable properties such as pharmacokinetic/dynamic and or physicochemical and/or other drug like profiles to advance into clinics.
A · US 2015/0218187 A1 · ¶ 6
These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).
A · US 2015/0218187 A1 · ¶ 1
At present, there are no drugs approved for treating NASH.
B · US 2021/0032249 A1 · ¶ 4
ASK1 inhibitors have great potential for the clinical treatment of NASH, and have potential valuable application in the treatment of other diseases including neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune metabolic diseases and the like.
B · US 2021/0032249 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356851 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356851/, SHA-256 3feff9ffe0befbf389ebdc6358f6eb2070ddc2bb7f8e2c44e5c1f8eb41702068
First published
Permanent addresshttps://patent.fyi/US20260356851/
Content fingerprint (SHA-256)3feff9ffe0befbf389ebdc6358f6eb2070ddc2bb7f8e2c44e5c1f8eb41702068
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi